A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Recruiting Status:
Recruiting
Age:
18+
A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton’s Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed/Refractory B-cell Malignancies
'